ReviewFrontiers in aging neuroscience2026
Intervention of ginseng-derived macromolecular drugs in Alzheimer's disease: exploring mechanisms and assessing potential.
Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder for which effective treatments remain elusive. This review aims to explore the roles, mechanisms, and therapeutic potential of three principal ginseng components, including ginseng polysaccharides (GPS), ginseng proteins (GP), and ginseng glycoproteins (GGP), in the prevention and management of AD. We systematically reviewed recent literature related to these components in AD research. By analyzing evidence from cellular experiments, animal models, and preliminary clinical studies, we evaluated their effects on core pathological processes. These ginseng-derived compounds exert neuroprotective effects via multiple pathways. Specifically, they inhibit the aggregation of amyloid-β (Aβ) and reduce the hyperphosphorylation of tau protein. Furthermore, they demonstrate significant anti-neuroinflammatory and antioxidant activities, which protect neurons from damage and enhance cognitive functions, including memory and learning. The efficacy of these components has been consistently demonstrated across various AD experimental models. In conclusion, GPS, GP, and GGP exhibit promise as multitarget therapeutic agents against AD, underscoring a potential pathway for developing novel natural product-based treatments. Although current preclinical results are promising, further rigorous clinical trials are necessary to validate their efficacy and safety in humans. Therapeutic strategies targeting these components may therefore offer new hope for AD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.